Regeneron Pharmaceuticals, Inc. logo

Regeneron Pharmaceuticals, Inc. (REGN)

Market Closed
10 Jul, 20:00
NASDAQ (NGS) NASDAQ (NGS)
$
559. 76
+7.18
+1.3%
$
58.1B Market Cap
24.52 P/E Ratio
0% Div Yield
827,334 Volume
42.79 Eps
$ 552.58
Previous Close
Day Range
550.11 566.2
Year Range
476.49 1,211.2
Want to track REGN and more in your Portfolio? 🎯
Sign up for Marketlog, a portfolio tracker that will exceed your expectations!
Earnings results expected in 20 days

Summary

REGN closed today higher at $559.76, an increase of 1.3% from yesterday's close, completing a monthly increase of 13.98% or $68.67. Over the past 12 months, REGN stock lost -22.35%.
REGN is not paying dividends to its shareholders.
The last earnings report, released on Apr 30, 2025, exceeded the consensus estimates by 0%. On average, the company has surpassed earnings expectations by 0.49%, based on the last three reports. The next scheduled earnings report is due on Jul 30, 2025.
The stock of the company had never split.
The company's stock is traded on 13 different exchanges and in various currencies, with the primary listing on NASDAQ (NGS) (USD).

REGN Chart

Chart

Chart with 60 data points.
The chart has 1 X axis displaying categories.
The chart has 2 Y axes displaying values, and values.
End of interactive chart.
Regeneron Pharmaceuticals: My Highest Conviction Pharma Pick For 2025

Regeneron Pharmaceuticals: My Highest Conviction Pharma Pick For 2025

Regeneron Pharmaceuticals, Inc.'s stock continues to remain in the accumulation phase even after the setbacks associated primarily with itepekimab and Eylea. At the same time, Dupixent will remain Regeneron's key "cash cow" and its savior, the profit from sales of which will rise sharply in 2027. From its oncology franchise, I highlight Lynozyfic, which received its first FDA approval on July 2, and Libtayo, whose sales reached $285 million in Q1 2025.

Seekingalpha | 10 hours ago
FDA Grants Accelerated Approval to Regeneron's Blood Cancer Drug

FDA Grants Accelerated Approval to Regeneron's Blood Cancer Drug

REGN scores FDA approval for Lynozyfic in tough-to-treat multiple myeloma, bolstering its oncology pipeline amid Eylea headwinds.

Zacks | 1 week ago
US FDA approves Regeneron's blood cancer therapy

US FDA approves Regeneron's blood cancer therapy

The U.S. Food and Drug Administration has approved Regeneron's cancer therapy, the company said on Wednesday, providing another treatment option for patients with a recurring and common form of blood cancer.

Reuters | 1 week ago

Regeneron Pharmaceuticals, Inc. Dividends

REGN is not paying dividends to its shareholders.

Regeneron Pharmaceuticals, Inc. Earnings

30 Jul 2025 (In 2 weeks) Date
8.53
Cons. EPS
-
EPS
30 Apr 2025 Date
-
Cons. EPS
-
EPS
31 Jan 2025 Date
11.38
Cons. EPS
12.07
EPS
31 Oct 2024 Date
11.69
Cons. EPS
12.46
EPS
1 Aug 2024 Date
10.61
Cons. EPS
11.56
EPS
REGN is not paying dividends to its shareholders.
30 Jul 2025 (In 2 weeks) Date
8.53
Cons. EPS
-
EPS
30 Apr 2025 Date
-
Cons. EPS
-
EPS
31 Jan 2025 Date
11.38
Cons. EPS
12.07
EPS
31 Oct 2024 Date
11.69
Cons. EPS
12.46
EPS
1 Aug 2024 Date
10.61
Cons. EPS
11.56
EPS

Regeneron Pharmaceuticals, Inc. (REGN) FAQ

What is the stock price today?

The current price is $559.76.

On which exchange is it traded?

Regeneron Pharmaceuticals, Inc. is listed on NASDAQ (NGS).

What is its stock symbol?

The ticker symbol is REGN.

Does it pay dividends? What is the current yield?

Yes, It pays dividends and the current yield is 0%.

What is its market cap?

As of today, the market cap is 58.1B.

What is the earnings per share?

The EPS is 8.53.

When is the next earnings date?

The next earnings report will release on Jul 30, 2025.

Has Regeneron Pharmaceuticals, Inc. ever had a stock split?

No, there has never been a stock split.

Regeneron Pharmaceuticals, Inc. Profile

Biotechnology Industry
Healthcare Sector
Leonard S. Schleifer CEO
NASDAQ (NGS) Exchange
75886F107 Cusip
US Country
15,158 Employees
- Last Dividend
- Last Split
2 Apr 1991 IPO Date

Overview

Regeneron Pharmaceuticals, Inc. is a biotechnology firm that is renowned for its dedication to discovering, inventing, developing, manufacturing, and commercializing medicines to combat a variety of diseases globally. Since its inception in 1988, the company has been at the forefront of innovative treatments, striving to address the unmet medical needs of patients around the world. With its headquarters nested in Tarrytown, New York, Regeneron has made a significant impact in the pharmaceutical industry by delivering life-changing medicines to patients in need.

Products and Services

Regeneron Pharmaceuticals, Inc. offers a diverse portfolio of products aimed at treating a wide range of diseases, including but not limited to, eye diseases, allergies and inflammations, cardiovascular and metabolic conditions, infectious diseases, rare diseases, cancers, pain, and hematologic conditions.

  • EYLEA Injection: Used for the treatment of wet age-related macular degeneration, diabetic macular edema, myopic choroidal neovascularization, diabetic retinopathy, neovascular glaucoma, and retinopathy of prematurity.
  • Dupixent Injection: Offers relief for adults and children suffering from atopic dermatitis and asthma, targeting the underlying inflammation and immune system response.
  • Libtayo Injection: Approved for the treatment of metastatic or locally advanced cutaneous squamous cell carcinoma, providing a much-needed option for patients with this serious skin cancer.
  • Praluent Injection: Aimed at adults with heterozygous familial hypercholesterolemia or clinical atherosclerotic cardiovascular disease, this medication works by reducing LDL cholesterol levels.
  • REGEN-COV: For patients with COVID-19, offering a treatment option to help reduce the severity of the disease and potential hospitalization.
  • Kevzara Solution: Designed for adults with rheumatoid arthritis, Kevzara works by interfering with the inflammatory pathway to reduce symptoms and slow disease progression.
  • Inmazeb Injection: The first FDA-approved treatment for infection caused by Zaire ebolavirus, offering hope to patients facing this deadly disease.
  • ARCALYST Injection: Treats cryopyrin-associated periodic syndromes, including familial cold auto-inflammatory syndrome and Muckle-Wells syndrome, by targeting the body’s inflammatory response.
  • ZALTRAP Injection: Used in combination with chemotherapy for the treatment of metastatic colorectal cancer, aiming to slow the spread of the disease.

In addition to these products, Regeneron is continuously working on developing new treatments for a variety of diseases, demonstrating their commitment to innovation and improving patient health worldwide.

Contact Information

Address: 777 Old Saw Mill River Road
Phone: 914 847 7000